Nurix Therapeutics (NRIX) Competitors $9.82 -0.03 (-0.30%) Closing price 04:00 PM EasternExtended Trading$9.82 -0.01 (-0.05%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRIX vs. AKRO, MOR, SWTX, PTGX, CPRX, MRUS, ALVO, APLS, SRRK, and CRNXShould you be buying Nurix Therapeutics stock or one of its competitors? The main competitors of Nurix Therapeutics include Akero Therapeutics (AKRO), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Protagonist Therapeutics (PTGX), Catalyst Pharmaceuticals (CPRX), Merus (MRUS), Alvotech (ALVO), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Nurix Therapeutics vs. Akero Therapeutics MorphoSys SpringWorks Therapeutics Protagonist Therapeutics Catalyst Pharmaceuticals Merus Alvotech Apellis Pharmaceuticals Scholar Rock Crinetics Pharmaceuticals Nurix Therapeutics (NASDAQ:NRIX) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, analyst recommendations, earnings, risk, valuation, community ranking, profitability and institutional ownership. Is NRIX or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -354.85%. Akero Therapeutics' return on equity of -32.46% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-354.85% -53.65% -38.59% Akero Therapeutics N/A -32.46%-29.83% Which has more volatility and risk, NRIX or AKRO? Nurix Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Does the media favor NRIX or AKRO? In the previous week, Nurix Therapeutics had 19 more articles in the media than Akero Therapeutics. MarketBeat recorded 33 mentions for Nurix Therapeutics and 14 mentions for Akero Therapeutics. Akero Therapeutics' average media sentiment score of 1.08 beat Nurix Therapeutics' score of 0.55 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 7 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive Akero Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, NRIX or AKRO? Akero Therapeutics has lower revenue, but higher earnings than Nurix Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$56.42M13.16-$193.57M-$2.80-3.48Akero TherapeuticsN/AN/A-$151.76M-$3.75-10.03 Does the MarketBeat Community believe in NRIX or AKRO? Akero Therapeutics received 32 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 78.70% of users gave Nurix Therapeutics an outperform vote while only 65.36% of users gave Akero Therapeutics an outperform vote. CompanyUnderperformOutperformNurix TherapeuticsOutperform Votes8578.70% Underperform Votes2321.30% Akero TherapeuticsOutperform Votes11765.36% Underperform Votes6234.64% Do analysts recommend NRIX or AKRO? Nurix Therapeutics presently has a consensus price target of $30.44, indicating a potential upside of 212.57%. Akero Therapeutics has a consensus price target of $76.29, indicating a potential upside of 102.78%. Given Nurix Therapeutics' higher probable upside, equities research analysts clearly believe Nurix Therapeutics is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.84Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryNurix Therapeutics beats Akero Therapeutics on 8 of the 15 factors compared between the two stocks. Remove Ads Get Nurix Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRIX vs. The Competition Export to ExcelMetricNurix TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$742.54M$6.31B$5.32B$7.60BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-3.376.8021.7517.84Price / Sales13.16223.34378.5093.37Price / CashN/A65.6738.1534.64Price / Book1.315.836.444.01Net Income-$193.57M$141.86M$3.20B$247.23M7 Day Performance5.18%9.23%6.58%7.44%1 Month Performance-28.33%-12.42%-8.54%-6.13%1 Year Performance-37.00%-12.15%10.13%-0.02% Nurix Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRIXNurix Therapeutics2.1103 of 5 stars$9.82-0.3%$30.44+210.0%-41.2%$748.64M$56.42M-3.40300Earnings ReportGap DownAKROAkero Therapeutics4.307 of 5 stars$35.97-2.1%$76.29+112.1%+69.5%$2.86BN/A-9.5930Positive NewsHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.0543 of 5 stars$36.99-5.4%$73.20+97.9%-12.4%$2.77B$191.59M-10.63230Positive NewsHigh Trading VolumePTGXProtagonist Therapeutics3.8077 of 5 stars$43.21-2.8%$62.56+44.8%+66.5%$2.65B$434.43M16.24120Positive NewsCPRXCatalyst Pharmaceuticals4.6047 of 5 stars$21.81-5.5%$32.29+48.0%+49.8%$2.65B$491.73M18.4880Positive NewsGap DownHigh Trading VolumeMRUSMerus2.8304 of 5 stars$37.39-1.9%$85.31+128.2%+1.4%$2.58B$36.13M-9.4737Positive NewsALVOAlvotech1.7084 of 5 stars$8.32-2.1%$18.00+116.3%-30.3%$2.51B$489.68M-4.501,026Analyst RevisionGap DownAPLSApellis Pharmaceuticals4.1441 of 5 stars$19.80-0.9%$45.59+130.2%-62.7%$2.49B$781.37M-9.75770Gap DownSRRKScholar Rock3.8819 of 5 stars$26.04-3.2%$42.67+63.9%+115.1%$2.47B$33.19M-11.08140Positive NewsCRNXCrinetics Pharmaceuticals3.5849 of 5 stars$26.38-1.9%$73.00+176.7%-33.2%$2.45B$1.04M-7.07210Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies AKRO Alternatives MOR Alternatives SWTX Alternatives PTGX Alternatives CPRX Alternatives MRUS Alternatives ALVO Alternatives APLS Alternatives SRRK Alternatives CRNX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRIX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NRIX Stock Free NRIX Stock Alerts